Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168686 · ClinicalTrials.gov registry record · Phase 1
Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency
A Phase 1 study, sponsored by Adverum Biotechnologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02168686 is a Phase 1 study that has completed, run by Adverum Biotechnologies. The registered enrollment target is 6 participants.
The verdict
NCT02168686, a Phase 1 study, has completed, sponsored by Adverum Biotechnologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The ADVANCE study is being conducted by Adverum Biotechnologies, Inc. as an open-label, multicenter, dose-escalation study in order to assess the safety and protein expression of ADVM-043 following a single intravenous or intrapleural administration.
Interventions
- GENETIC ADVM-043
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2019-08-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02168686
The ClinicalTrials.gov registry entry for NCT02168686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adverum Biotechnologies, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADVM-043 is the first listed.
NCT02168686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02168686 about?
NCT02168686 is a clinical study titled "Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency". The ADVANCE study is being conducted by Adverum Biotechnologies, Inc. as an open-label, multicenter, dose-escalation study in order to assess the safety and protein expression of ADVM-043 following a single intravenous or intrapleural administration.
What is the current status of trial NCT02168686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-11-28. Estimated completion is 2019-08-29.
What interventions are being tested in trial NCT02168686?
The interventions under investigation include: ADVM-043 (GENETIC).
Who is sponsoring clinical trial NCT02168686?
This trial is sponsored by Adverum Biotechnologies, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.